Latest News

27

Mar2023

Mohammad Hirmand, MD

0  
by webmaster / / BOD
Dr. Hirmand has served on the Company’s board of directors since March of 2023 and is a co-founder of Avenzo Therapeutics, a privately held oncology company, and serves as its executive vice president and chief medical officer.  Previously, Dr. Hirmand served as executive vice president and chief medical officer of Turning ... Read More
March 27, 2023

26

Mar2023

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

0  
by John Copertino / / Publications
March 26, 2023

26

Mar2023

Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT

0  
by John Copertino / / Publications
March 26, 2023

13

Feb2023

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

0  
by webmaster / / Publications
February 13, 2023

16

Jan2023

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

0  
by John Copertino / / Publications
January 16, 2023

11

Nov2022

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

0  
by / / Publications
November 11, 2022

11

Nov2022

Management of adverse events in the AMPECT trial of nab-sirolimus for the treatment of advanced malignant perivascular epithelioid cell neoplasm (PEComa)

0  
by / / Publications
November 11, 2022

11

Nov2022

Study-end analysis from AMPECT, an open-label, phase 2 registration trial of patients with advanced malignant PEComatreated with nab-sirolimus, showing durability of response and long-term safety

0  
by / / Publications
November 11, 2022

27

Oct2022

KRAS G12C-Mutated NSCLC and Bladder Cancer Xenografts Treated With Sotorasib and Adagrasib in Combination With the mTOR Inhibitor nab-Sirolimus Show Improved Antitumor Activity

0  
by / / Publications
October 27, 2022

15

Oct2022

nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program

0  
by / / Publications
October 15, 2022